Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Collagenase clostridium histolyticum is an injectable biologic enzyme produced by the bacterium Clostridium histolyticum. It is used to break down collagen in fibrous tissue and is indicated for the treatment of Dupuytren's contracture with a palpable cord and Peyronie's disease with a palpable plaque and curvature deformity in men. Additionally, it has been approved as Qwo for the treatment of moderate to severe cellulite in adult women. The mechanism of action involves enzymatic hydrolysis of collagen types I and III, leading to disruption of abnormal fibrous tissue or plaques. The drug was developed by Endo International.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on collagenase clostridium histolyticum.